About EMBO Molecular Medicine
=============================

EMBO Molecular Medicine is a peer-reviewed journal dedicated to a new research discipline at the interface between clinical research and basic biology. It offers clinicians and researchers in this area the opportunity to publish their best work in a broadly distributed and highly visible forum, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. In addition to research articles, the Journal will publish editorials and review articles in innovative formats that target a broad and non-specialized audience.

In line with EMBO\'s longstanding tradition of openness and objectivity, authors will be offered a fair, transparent and rapid editorial and review process. Like EMBO\'s other publications, the Journal will be staffed by professional, Ph.D. level scientists, advised by a renowned group of Senior Editors and an expert, highly respected Advisory Editorial Board composed of researchers and clinicians.

Aims and scope
==============

*EMBO Molecular Medicine* is dedicated to the publication of the results of original, cutting-edge research in the field of Molecular Medicine of interest to medical and basic scientists. It will give priority to those articles that provide novel and relevant molecular insight into the cellular and systemic processes that underlie defined human diseases and that offer new perspectives for clinical application at the levels of prevention, diagnosis, treatment and/or therapy. The Journal publishes full-length research articles and short-format Reports relevant to all fields of clinical medicine and their related research areas in basic biology. Studies based on model organisms also fall within the scope of the Journal, provided that the results presented are evidently and directly relevant to human diseases. Potential authors of Reviews and other front-half materials should contact the Editorial Office before submission.

Review process
==============

Similar to the review process employed by other EMBO journals, the editorial process of EMBO Molecular Medicine involves careful scrutiny and close assessment of each manuscript as soon as possible after its submission and subsequent assignment to an editor. The editor will carefully read each paper, make a check of background literature, and discuss the strengths and weaknesses of the work with other members of the editorial team. This process results in an initial decision either to reject editorially, to request expert advice, or to proceed with an in-depth review. Rejections will be documented in detailed decision letters.

Only those manuscripts considered to be strong candidates for publication will be subjected to in-depth review. They will normally be assessed by three reviewers who are specialized in the area(s) of research covered. Reviewers are asked to comment on the overall novelty of the manuscript, its significance to the field, its medical / clinical relevance, the technical quality of the experimental data, and the soundness of the conclusions drawn. Reviewers are also asked to make suggestions of changes that would strengthen the paper. Editorial decisions on the suitability or otherwise of the reviewed manuscripts for publication will be based on a balanced evaluation of all reviewer reports with, if necessary, additional advice from a Senior Editor or member of the Advisory Editorial Board.

Article formats
===============

*Editorials and Perceptions* are opinion pieces that focus on important issues regarding Biomedical research, its community and human health in general. Editorials are written only by our Editors, whereas Perceptions are normally invited by the journal editors.

*Closeup* articles are inside looks on a specific development \[often an original article(s) published in our Journal or elsewhere\] in our understanding of a clinically relevant issue.

*Reviews* provide the reader with a broad and scholarly overview of a particular topic related to molecular medicine, while noting the most recent developments in the field. They are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information.

*In Focus* articles are topical, personalized reviews that focus on a specific topic. Authors are encouraged to share personal views and to speculate about the implications or future directions of research in the field.

*Bridge the Gap* articles will help both basic and clinical researchers to better understand each other\'s perspectives and define common goals. Authors are encouraged to suggest new strategies and avenues of investigation that may fill the gaps they perceive as existing between the discovery of a biological mechanism and the application of the resultant concepts to the better understanding of a specific disease, its diagnosis, prevention or treatment. Alternatively, from a clinical perspective, authors might highlight disease phenotypes they consider to be poorly understood in molecular terms and suggest lines of research that would lead to such understanding.

*Research articles* report novel molecular research highly relevant to the understanding, prevention, treatment or cure of human diseases.

*Reports* are concise manuscripts that highlight a specific finding, model or methodology with a high impact on the field of molecular medicine.

Front half content
==================

*Editorials* and *Perceptions*- are opinion pieces that focus on issues of high importance to Biomedical research, the corresponding research communities and Human health in general. These are short pieces of approximately 1000 words. *Editorials* are written only by our Editors, while *Perceptions* are normally invited by the journal editors. Please contact the Editorial Office should you wish to submit a Perception.

*Closeup* articles are short, focussed highlights of a specific development \[often an original article(s) published in our Journal or elsewhere\] in our understanding of a clinically relevant issue. They are aimed at non-specialist readers and are supplemented with explanatory text and online links to relevant sources of additional information. The total character count for a *Closeup,* including spaces, figure legends and references, may not exceed 10,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage authors to include an explanatory figure. The total length of the *Closeup* when printed should not exceed two pages. Please bear this limit in mind when preparing figures or tables. *Closeups* are usually commissioned by our editors. We are also open to original un-invited submissions but would urge you to contact the Editorial Office beforehand. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

*Reviews* provide the reader with the background to, and a broad overview of a particular topic related to molecular medicine, while noting the most recent developments in the field. They are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information. Reviews must be based on published data. The total character count for a Review, including spaces, figure legends and references, may not exceed 50,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage authors to include explanatory figures, models and Tables. Suggestions may be submitted to the Editorial Office in the form of a one-page proposal for consideration, but contributions are usually commissioned by the editors. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

*In Focus* articles are topical, personalized reviews that focus on a specific topic. Authors are encouraged to share personal views and to speculate about the implications or future directions of research in the field. The articles are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information. The total character count for an In Focus, including spaces, figure legends and references, may not exceed 30,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage authors to include explanatory figures, models and Tables. Suggestions may be submitted to the Editorial Office in the form of a one-page proposal for consideration, but contributions are usually commissioned by the editors. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

*Bridge the Gap* articles will help both basic and clinical researchers to better understand each other\'s perspectives and define common goals. Authors are encouraged to suggest new strategies and avenues of investigation that may fill the gaps they perceive as existing between the discovery of a biological mechanism and the application of the resultant concepts to the better understanding of a specific disease, its diagnosis, prevention or treatment. Alternatively, from a clinical perspective, authors may highlight disease phenotypes that they consider to be poorly understood in molecular terms and suggest lines of research that would lead to such understanding. *Bridge the Gap* articles are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information. The total character count, including spaces, figure legends and references, may not exceed 30,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage including explanatory figures, models and Tables. Suggestions may be submitted to the Editorial Office in the form of a one-page proposal for consideration, but contributions are usually commissioned by the editors. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

Primary research articles and reports
=====================================

Prior to submission
-------------------

To avoid unnecessary delays in the review process for research articles and reports, please consider the following policies carefully before you submit your manuscript.

Availability of published material
----------------------------------

It is understood that by publishing a paper in *EMBO Molecular Medicine* the authors agree to make freely available to their colleagues in academic or clinical research any of the organisms, viruses, cells, nucleic acids, antibodies, and other reagents that were used in the research reported and that are not available from commercial suppliers.

Bioethics
---------

For primary research manuscripts in *EMBO Molecular Medicine* that report experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include in the Supportive Information (methods) section (or, if brief, within of the print/online article at an appropriate place), a statement identifying the institutional and/or licensing committee approving the experiments, including any relevant details. For experiments involving human subjects, authors must identify the committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all subjects.

Conflicts of interest
---------------------

In the interests of transparency and to help reviewers assess any potential bias, *EMBO Molecular Medicine* requires all authors to declare any competing commercial interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Please refer to the 'Guide for Referees' for details.

Electronic manipulation of images
---------------------------------

Digital image enhancement is acceptable practice. However, during manipulation of images a positive relationship between the original data and the resulting electronic image must be maintained to avoid the presentation of unrepresentative data as well as the loss of meaningful signals. If a figure has been subjected to significant electronic manipulation, the specific nature of the enhancements must be noted in the figure legend or in the 'Materials and methods' section. The Editors reserve the right to request original versions of the figures and the original images that were used to assemble the figure from the authors of a paper under consideration. Rejection of the manuscript may occur in cases where the original data is not presented or was misrepresented. The following publication is a good reference for acceptable practices: Rossner M, Yamada KM (2004) What\'s in a picture? The temptation of image manipulation. J Cell Biol 166: 11-15. Please ensure your submission complies with the good-practice standards described therein.

Submission to public databases
------------------------------

*EMBO Molecular Medicine* will only review and publish manuscripts if the authors agree to make all data that cannot be published in the Journal itself (e.g. novel nucleotide sequences, structural data or data from large-scale gene expression experiments) freely available in one of the public databases (see Submission to public databases below). Accession codes must be provided at the time a revised manuscript is returned to the Editorial Office. To avoid delays in publication of the manuscript, we encourage authors to deposit relevant data in public databases prior to submission. The authors may request that the data be stored in a confidential section of the database, in which they can request passwords from the database administrators and these should be passed on to the Editorial Office to allow the editors and referees to anonymously access the information during the review process. Further information on submitting to public databases can be found here.

Supportive information for the editors and the reviewers
--------------------------------------------------------

All manuscripts under review or accepted for publication elsewhere should accompany the submission if they are relevant to its scientific assessment. Authors should also provide at submission any kind of supplementary material (supportive information) that will aid the review process.

Submission
----------

The Editors reserve the right to return manuscripts that are not in accordance with the following instructions.

Manuscripts must be written in clear and concise English and be intelligible to a broad readership. Non-native speakers of English may find this section useful. Authors may mention the names of potential reviewers to include in or to exclude from the review process when submitting their manuscript. Papers are, in general, reviewed by three appropriate referees selected by the Editors and based on their reports, the decision concerning publication, revision or rejection is taken. Papers may be returned to authors without review if in the judgment of the Editors they fail to meet the criteria of wide medical significance and novelty, or if they are considered too preliminary.

*We will acknowledge receipt of a submitted manuscript by e-mail as soon as an Editor has been assigned to the paper. All further correspondence will also be by e-mail*.

The Editorial Office will handle **pre-submission inquiries** but does not encourage enquiries based simply on abstracts. This is because it is often difficult to judge a paper based on limited information in an abstract and/or covering letter and without seeing the relevant data. We prefer instead submissions of full manuscripts \[regardless of their format\] or of an abstract and accompanying figures and figure legends. This allows us to make a more informed decision on the manuscript and to give authors a rapid decision in case we feel the manuscript is not appropriate for the Journal, or otherwise invite submission of the manuscript.

General format
==============

The total character count (including spaces) for a full-length ***Research article***, including the title page, abstract, figure legends and references (excluding tables and supplementary material) may not exceed 60,000 characters (the exact character count to be printed on the title page). For a Report, the character limit is 27,500 characters. Manuscripts exceeding these limits at submission may be returned to the authors for amendment. Please consider including a supportive information section (see below) if your manuscript exceeds the above limitations. The total length of an article when published should not exceed 10 pages for a research article, and 7 pages for a *Report*. Please bear in mind the total page limits when preparing figures and tables.

Please use 'Times' font at 10 or 12 point size for all text pages, 'Symbol' font for non-Latin characters, and 'Arial or Sans-serif' font for lettering on figures. 'Courier' font may be used for sequence data. Number each page at the bottom (Title page is 1). Manuscripts of both full-length and Report formats should be divided into the following sections:

1.  Title page

2.  Abstract

3.  Introduction

4.  Results

5.  Discussion

6.  Materials and methods

7.  Acknowledgements

8.  References

9.  Figure legends

10. Figures

11. Tables

12. Supportive information

Title page
----------

The title should be short and informative, and should not contain any abbreviations. The total length of the title should not exceed 175 characters (including spaces). Serial titles are not accepted.

The full name of each author should be given. Numbers in superscript should be used to link the authors to their respective affiliations. Complete details regarding affiliations, such as department, institution, city with postal code and country, should be provided for each author. Any changes of address may also be given in numbered footnotes. It is possible to name two authors as the correspondents of a published article; at the time of submission, however, it is important to indicate only a single author to whom all correspondence should to be addressed, together with an e-mail address, telephone and fax numbers.

The title page must also state the precise character count of the manuscript. Please provide a running title of not more than 50 characters including spaces. Up to five keywords, which may or may not appear in the title, should be given in alphabetical order, below the abstract, each separated by a slash (/).

Abstract
--------

This should be a single paragraph not exceeding 175 words. The Abstract should be comprehensible to readers before they have read the paper, and abbreviations should be avoided. Reference citations within the abstract are not permitted.

Introduction
------------

The Introduction should be succinct and provide only the necessary background information, rather than a comprehensive review of the specific field. It should not contain subheadings.

Results and discussion
----------------------

These sections should each be divided by subheadings and may be combined into one section if appropriate.

Materials and methods
---------------------

This section should contain sufficient details so that all experimental procedures can be repeated by others, in conjunction with cited references. *EMBO Molecular Medicine* encourages detailed descriptions of methodology or additional materials to be included as Supportive information. This information should, however, not be of immediate importance for the understanding of the manuscript.

Acknowledgements
================

These should be placed at the end of the text and not in footnotes. Personal acknowledgements should precede those of institutions or agencies.

References
==========

Authors are responsible for the accuracy of the references. Published articles as well as those in press (please state the name of the journal and enclose a copy of the manuscript) may be included. In the text of the manuscript, a reference should be cited by author and year of publication; no more than two authors may be cited per reference; 'et al' should be used if there are more than two authors (Ferrier & Lunkes, 2003; Wiersdorff et al, 2000).

In the reference list, citations should be listed in alphabetical order and then chronologically, with the authors\' surnames and initials inverted; et al should not be used unless there are more than 10 authors. Publications by the same author(s) in the same year should be identified with a, b, c after the year of publication. The name of each journal should be abbreviated according to Index Medicus and italicized.

References should therefore be listed (and will subsequently appear in print) as follows:

Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE (2002) Aspirin and lung cancer in women. Br J Cancer 87: 49-53

Wendland J (2003) Analysis of the landmark protein Bud3 of Ashbya gossypii reveals a novel role in septum construction. EMBO rep 4: 200-204

a.  example of book chapter:

    1.  Price SR, Oubridge C, Varani G, Nagai K (1998) Preparation of RNA--protein complexes for X--ray crystallography and NMR. In RNA--Protein Interaction: Practical Approach, Smith C (ed) pp 37--74. Oxford: Oxford University Press

b.  example of book:

    1.  Sambrook J, Fritsch E & Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Press, Cold Spring Harbour, New York, USA

    2.  Citations to articles in press or only published online at the time of submission should be made as follows:

c.  example of article in press without doi:

    1.  Lim E-K, Ashford DA, Hou B, Jackson RG, Bowles DJ (2004) Arabidopsis glycosyltransferases as biocatalysts in fermentation for regioselective synthesis of diverse quercetin glucosides. Biotech Bioeng (in press)

d.  example of article in press with doi

    1.  Eng-Kiat Lim and Dianna J Bowles, A class of plant glycosyltransferases involved in cellular homeostasis, *EMBO Molecular Medicine* advance online publication 8 July 2004; doi:10.1038/sj.emboj.7600295

Personal communications (J Doe, personal communication, 2001) should be authorized in writing by those involved, and unpublished data should be cited as (J Smith and D Jones, unpublished data, 2001). Authors are responsible for requesting and presenting such authorizations. References to manuscripts in preparation or submitted, but not yet accepted, should be cited in the text as (C Lee and N Jones, in preparation), not as (C Lee and N Jones, submitted), and should not be included in the list of references.

Please download the Endnote Styles to format your manuscript at <http://www.endnote.com/support/enstyles.asp>

Figure legends
==============

All symbols and abbreviations used in the figure must be defined, unless they are common abbreviations or have already been defined in the text. Experimental details should, where possible, be given in the Materials and Methods section, and not repeated in the figure legends. The legends should not appear under the figures, but be gathered in a separate section (Figure legends) after the references.

Figures
=======

Figures should be labelled in consecutive Arabic numerals (1, 2, 3,). Figures should be submitted in a format that can be reduced to a width of 55--85mm or 120--175mm, and symbols and labels to a height of 1.5--2.0mm (after reduction). As far as possible, all lettering should be of the same size. Figure panels should be indicated by capital letters (A, B, C, etc.). The font size should be consistent within the Figures. Gridlines are not allowed except for log plots. Use Helvetica font for all the lettering, Courier font for sequence data and Symbol font for any symbols. Scale bars, rather than magnification factors, should be used, with the length of the bar defined in the legend rather than on the bar itself. In general, visual cues on the figure itself are preferred rather than verbal explanations (for example, 'broken line' or 'filled black triangles') in the legend. Each Figure must have a separate legend. The responsibility for providing permissions to reprint Figures and Tables and any associated costs rests entirely with the author.

Detailed instructions for the preparation of electronic figures are provided below (Illustrations).

Tables
======

Tables should be typed on separate sheets and numbered consecutively with Roman numerals (I, II, III, IV). Tables should be self-explanatory and include a brief descriptive title. Footnotes to tables indicated by lower-case superscript letters are acceptable, but they should not include extensive experimental details.

Supportive information
======================

Authors should ensure that supportive information is supplied in its FINAL format because this will not be subedited and will appear online exactly as originally submitted. It cannot be altered, nor new supportive information added, after the paper has been accepted for publication. Supportive information is peer-reviewed material directly relevant to the conclusions of an article that cannot be included in the printed version owing to space or format constraints. It is posted on the Journal\'s web site and linked to the article when the article is published and may consist of additional text, figures, movies or extensive tables.

The printed article must be complete and self-explanatory without the supportive information. Supportive information should enhance, but not be essential to, a reader\'s understanding of the paper. While EMBO Molecular Medicine encourages authors to supply additional, extensive descriptions of the materials and methods used in a study as supportive information, it is not permissible to move the entire 'Materials and methods' section (or any other section of the manuscript) into the online supplement. Supportive information must be supplied to the Editorial Office in its final form for peer review. Supportive information is not subedited, so authors should ensure that it is supplied ready for publication online. Please see below for acceptable file formats and sizes (Supportive information).

Supportive data describing the results of microarray studies or similar large-scale expression experiments should be deposited with one of the public databases (ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) or GEO (<http://www.ncbi.nlm.nih.gov/geo/>)) prior to submission of the paper. To avoid delays in publication of the manuscript, we encourage authors to deposit relevant data in public databases prior to submission. The authors may request that the data be stored in a confidential section of the database, for which they can request passwords from the database administrators, and these should be passed on to the Editorial Office to allow the editors and referees to anonymously access the information during the review process. Authors may submit the data in a MIAME format on CD-ROMs in a form accessible on different computer systems at the time of submission if they have not received passwords from the database administrators yet.

Conventions
===========

In general, the Journal follows conventions given in Scientific Style and Format: The CBE Manual for Authors, Editors and Publishers (1994) Cambridge University Press, Cambridge, UK, 6th edn. Please follow Chemical Abstracts and its indexes for chemical names. For guidance in the use of biochemical terminology follow the recommendations issued by the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature. In general, genotypes should be indicated in italics; phenotypes should not be italicized.

Abbreviations
=============

Try to restrict the use of abbreviations to SI symbols and those recommended by the IUPAC. Abbreviations should be defined in brackets after their first mention in the text, not in a list of abbreviations. Standard units of measurements (SI symbols) and symbols of chemical elements may be used without definition in the body of the paper. Abbreviations of standard biochemical compounds, e.g. ATP, DNA, nucleotides in nucleic acids, and amino acids in proteins, need not be defined.

How to submit
=============

We are using an online manuscript submission and tracking system, which can be accessed at: <http://embomolmed.msubmit.net>.

For original submissions, you will need to upload a Word file of the text of the manuscript (including figure legends), a PDF file containing all the figures and a cover letter.

Alternatively individual figure files can be uploaded separately but please note that this can be more time-consuming than a PDF submission. Additional supplementary files can also be uploaded when applicable (please refer to the section 'Supportive information' above).

Once you have submitted your files and the conversion is in progress, you may log off the Internet and come back later to check and approve the conversion. This process can take up to 5--10 minutes before the PDF, created in the conversion process, is ready for approval. Please remember that your manuscript will not be submitted until you have approved the converted files. To avoid any unnecessary delays, please refer to the most current electronic formatting guidelines when preparing your manuscript for submission. Authors using computer systems with non-Western type encoding are strongly encouraged to eliminate all occurrences of nonstandard fonts in both the manuscript and the figures. We suggest using only the fonts Times, Symbol, Courier and Helvetica.

Revisions
=========

When a manuscript is returned to authors for revision, the revised version should be submitted within 3 months of the authors\' receipt of the referee reports. If a revised manuscript is returned thereafter, it will generally be considered as a new submission. Additional time for revision can be granted upon request, at the Editors\' discretion. Only a single round of revision will be permitted. Authors will be provided with a URL in the letter of decision regarding the original version of the manuscript. Please use this URL for submission of revised manuscripts.

Format of text
==============

The Editorial Office will only accept text files in RTF or MS Word format. The final character count must be clearly indicated on the title page of the revised manuscript. Manuscripts that do not comply with the formatting guidelines above, or exceed the length restrictions, will not be considered and returned to the authors for amendment. Please submit the full text (including figure legends, tables and references) as an MS Word or RTF file, named "\<5-digit manuscript number\>.doc" or "\<5-digit manuscript number\>.rtf" (e.g. '48000.doc' or '48000.rtf').

Saving files with Microsoft Office 2007
---------------------------------------

Microsoft Office 2007 saves files in an XML format by default (file extensions .docx, .pptx and xlsx). Files saved in this format cannot be accepted for publication.

Save Word documents using the file extension .doc

Select the Office Button in the upper left corner of the Word 2007 Window and choose "Save As"Select "Word 97-2003 Document"Enter a file name and select "Save"

These instructions also apply to the new versions of Excel and PowerPoint.

Equations in Word must be created using Equation Editor 3.0

Equations created using the new equation editor in Word 2007 and saved as a "Word 97-2003 Document" (.doc) are converted to graphics and can no longer be edited. To insert or change an equation with the previous equation editor:

Select "Object" on the "Text" section of the "Insert" tabIn the drop-down menu - select "Equation Editor 3.0"

Do not use the "Equation" button in the "Symbols" section of the "Insert" tab.

Illustrations
=============

When submitting a revised manuscript, it is essential to include high-quality computer files for all figures, which will be used for the production process.

We can only accept one file per figure. Composite figures containing multiple panels must be collected into one file before submission and must be scaled such that they can be reproduced on a single printed page. The figure files must be labelled in the following way: 'Fig_1.eps', 'Fig_2.tif', 'Fig_3.psd', 'Fig_4.ai', etc. Please do not use an alternative labelling system and do not include the manuscript number in the file names.

Composite figures may be assembled in Adobe Photoshop or Illustrator and may be submitted in the default formats offered by these programs. If it is not possible to send artwork in the above formats, the Editorial Office can accept line drawings and composite figures in EPS format, and halftone figures in TIFF (please be sure to use LZW compression) or EPS formats. High-quality PDF or MS PowerPoint files for figures may also be acceptable.

All lettering should be done using standard fonts (Helvetica, Times, Symbol, Courier) and retained in a separate layer (if possible) so that the production team can adapt any labels to the Journal\'s style if necessary. All fonts used for labelling the figures should also be embedded in the final files if the software package offers this option.

All colour artwork must be submitted in CMYK colour mode. When converting files from RGB, please consider that the final figures will be printed on coated paper, using Euroscale process inks. If you are not familiar with these specifications, or are not sure how to apply them within your software package, please consult a local graphics expert. Ultimately, it is important that all colours look satisfactory after conversion to CMYK, both on screen and when printed on different printers. Figures supplied electronically should have the following resolution:

Type ResolutionGraphs 800--1200 DPIPhotos 400--800 DPIColour (only CMYK) 300--400 DPI

Free colour on the web
======================

All figures where colour is required for proper understanding of the data presented must be printed in colour. In certain cases, if colour is not mandatory, authors may choose to have their figures printed in black and white but have colour versions of individual figures on the html and online PDF version of the article. This option is subject to prior approval by the editor.

Supportive information
======================

Supportive information must be supplied in one of the following file formats:

--Quick Time files (.mov)--Graphical image files (.gif)--HTML files (.html)--MPEG movie files (.mpg)--JPEG image files (.jpg)--Sound files (.wav)--Plain ASCII text (.txt)--Acrobat files (.pdf)--MS Word documents (.doc)--Postscript files (.ps)--MS Excel spreadsheet documents (.xls)--PowerPoint files (.ppt)

Unfortunately, we cannot accept TeX and LaTeX.

Data supplied in other formats cannot be considered for online publication. File sizes must be as small as possible, so that they can be downloaded quickly. The number of files should be limited to 10 and individual files should not be larger than 1MB (PDF or Excel files), 8MB (movie files) and 6MB (image files). Please provide figure legends below the Figure in question. Please seek advice from the Editorial Office before sending files larger than our maximum size to avoid delays in reviewing and publication.

It is important that you name the supportive files 'Sup_1.pdf', 'Sup_2.xls', 'Sup_3.mpg', etc. Please do not use an alternative labelling system. The supportive information may not be altered, nor new supplementary information added, after the paper has been accepted for publication. Please refer to each supportive item in the body of the text or the figure legends. You should also include the text 'Supportive information is available at *EMBO Molecular Medicine* Online' at the end of the article and before the references.

Submission to public databases
==============================

*EMBO Molecular Medicine* requires submission of novel sequence, structural and large scale analysis data to the appropriate public databases. We will not accept an article for publication until the relevant entry codes have been provided. These must be quoted in the text of the article. Please note that this policy applies even to short stretches of novel sequence information (e.g. epitopes, functional domains, genetic markers or haplotypes). Such short novel sequences must include surrounding sequence information in order to provide context. The sequences of all RNAi, antisense and morpholino probes must be included in the paper, or deposited in a public database with the accession number quoted. When an unpublished library is included in the paper, sequences of the probes central to the conclusions of the paper must be presented.

Sequence data
-------------

Nucleotide sequence data can be submitted in electronic form to any one of the three major collaborative databases:

**DDBJ:** DNA Data Bank of Japan, Center for Information Biology, National Institute of Genetics, Mishima, Shizuoka 411, Japan. Tel: +81 559 81 6853; Fax: +81 559 81 6849; Email: <http://www.ddbjsub@ddbj.nig.ac.jp> (for data submissions); <http://www.ddbj.nig.ac.jp>

**EMBL:** EMBL Nucleotide Sequence Submissions, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. Tel: +44 1223 494400; Fax: +44 1223 494472; E-mail: <http://www.datasubs@ebi.ac.uk>; <http://www.ebi.ac.uk>

**GenBank:** National Center for Biotechnology Information, National Library of Medicine, Building 38A, Room 8N-803, Bethesda, MD 20894, USA. Tel: +1 301 496 2475; Fax: +1 301 480 9241; E-mail: <http://www.gb-sub@ncbi.nlm.nih.gov>; <http://www.ncbi.nlm.nih.gov>.

The suggested wording for referring to accession number information in journal articles is 'These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession No. U12345'.

Structural data
---------------

*EMBO Molecular Medicine* accepts and follows the recommendations of the International Union of Crystallography (IUCr), with regard to the deposition and release of macromolecular structural data. These guidelines are set out in the article by the IUCr Commission on Biological Macromolecules in Acta Crystallographica (2000), D56, 2. In summary, they state that all publications must be accompanied by deposition of both the atomic coordinates and the structure-factor amplitudes in the appropriate database (PDB or NDB). In the case of low-resolution structures for which only a chain trace is reported, a set of C alpha positions and structure-factor amplitudes may be sufficient. For NMR structures, data deposited should include resonance assignments, and all restraints used in structure determination (NOEs, spin--spin coupling constants, amide exchange rates, etc.) and the derived atomic coordinates for both an individual structure and for a family of acceptable structures.

Structures of biological macromolecules solved by electron microscopy must be submitted to the EMDB database at <http://www.ebi.ac.uk/msd/Deposition.html>. For a brief description of the database, see Tagari *et al.* (2002) *Trends Biochem Sci* 27: 589.

Under exceptional circumstances and upon request, the Editors may grant a delay of up to 6 months for deposition or the release of deposited data.

Microarray data
---------------

Authors should refer to the MGED open letter specifying microarray standards (<http://www.mged.org/Workgroups/MIAME/miame_checklist.html>).

*EMBO Molecular Medicine* requires submission of microarray data to the ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) or GEO (<http://www.ncbi.nlm.nih.gov/geo/>) databases, and provision of accession numbers before acceptance of the paper for publication.
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